A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function

Hiddo J.L. Heerspink(University Medical Center Groningen), Dánae Duana Ávila(Universidad Autónoma del Estado de Hidalgo), Robert D. Toto(Southwestern Medical Center), Anna Maria Langkilde(AstraZeneca (Sweden)), Tom Greene(University Medical Center Groningen), A. Wassermann, A Marañón, Fan Fan Hou(Southern Medical University), John J.V. McMurray(University of Glasgow), César A. Arias(Houston Methodist), David Z.I. Cherney(University Health Network), Néstor H. García(Instituto de Investigaciones en Ciencias de la Salud), Glenn M. Chertow(Stanford Health Care), Rafaël Maldonado(FIND), Juan Oddino(University of Glasgow), C. David Sjöström(University Medical Center Groningen), Natalia Cluigt, Mikhail Kosiborod(AstraZeneca (Brazil)), Ricardo Correa‐Rotter(University Medical Center Groningen), Jamie P. Dwyer(University of Utah), Carolina Lúquez, David C. Wheeler(University College London), Andres Alvarisqueta(AbbVie (United States)), Cesar Javier Zaidman, Bergur V. Stefánsson(University Medical Center Groningen), Peter Rossing(Steno Diabetes Centers), Douwe Postmus(University Medical Center Groningen), Louise E. Sivak(The George Institute for Global Health), Lília Nigro Maia(Faculdade de Medicina de São José do Rio Preto), Dov Aizenberg, M. Maurich, Pablo Ramallo, Juan Carlos Santos, Pablo Raffaele, L.E. Gaite(The George Institute for Global Health), Ruben Garcia Duran, S. Solís, M. Mayer(Sorbonne Université), J. Bittar(University of Glasgow), Laura Maffei
Kidney International
September 21, 2021
Cited by 95


Related Papers